» Articles » PMID: 11809722

High Aggregate Burden of Somatic MtDNA Point Mutations in Aging and Alzheimer's Disease Brain

Overview
Journal Hum Mol Genet
Date 2002 Jan 26
PMID 11809722
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

The mitochondrial theory of aging proposes that mitochondrial DNA (mtDNA) accumulates mutations with age, and that these mutations contribute to physiological decline in aging and degenerative diseases. Although a great deal of indirect evidence supports this hypothesis, the aggregate burden of mtDNA mutations, particularly point mutations, has not been systematically quantified in aging or neurodegenerative disorders. Therefore, we directly assessed the aggregate burden of brain mtDNA point mutations in 17 subjects with Alzheimer's disease (AD), 10 elderly control subjects and 14 younger control subjects, using a PCR-cloning-sequencing strategy. We found that brain mtDNA from elderly subjects had a higher aggregate burden of mutations than brain mtDNA from younger subjects. The average aggregate mutational burden in elderly subjects was 2 x 10(-4) mutations/bp. The bulk of these mutations were individually rare point mutations, 60% of which changed an amino acid. Control experiments ensure that these results were not due to artifacts arising from PCR error, mistaken identification of nuclear pseudogenes or ex vivo oxidation. Cytochrome oxidase activity correlated negatively with increasing mutational burden. These findings significantly bolster the mitochondrial theory of aging.

Citing Articles

Cryptic mitochondrial DNA mutations coincide with mid-late life and are pathophysiologically informative in single cells across tissues and species.

Green A, Klimm F, Marshall A, Leetmaa R, Aryaman J, Gomez-Duran A Nat Commun. 2025; 16(1):2250.

PMID: 40050638 PMC: 11885543. DOI: 10.1038/s41467-025-57286-8.


Production of Amyloid-β in the Aβ-Protein-Precursor Proteolytic Pathway Is Discontinued or Severely Suppressed in Alzheimer's Disease-Affected Neurons: Contesting the 'Obvious'.

Volloch V, Rits-Volloch S Genes (Basel). 2025; 16(1.

PMID: 39858593 PMC: 11764795. DOI: 10.3390/genes16010046.


A Commentary on Mitochondrial Dysfunction and Compromised DNA Repair in Neurodegeneration: The Emerging Role of FUS in ALS.

Kodavati M, Hegde M Neurosci Insights. 2024; 19:26331055241305151.

PMID: 39679063 PMC: 11645713. DOI: 10.1177/26331055241305151.


Quintessential Synergy: Concurrent Transient Administration of Integrated Stress Response Inhibitors and BACE1 and/or BACE2 Activators as the Optimal Therapeutic Strategy for Alzheimer's Disease.

Volloch V, Rits-Volloch S Int J Mol Sci. 2024; 25(18).

PMID: 39337400 PMC: 11432332. DOI: 10.3390/ijms25189913.


ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies.

Volloch V, Rits-Volloch S Int J Mol Sci. 2024; 25(11).

PMID: 38892224 PMC: 11172602. DOI: 10.3390/ijms25116036.